consistent cooperation than studies done in Canada. He said his study could not have been done in a richer country, where more paperwork and management of patients is required in clinical trials. His team also had the luxury of treating patients in the hospital, where they could be watched, for seven days straight. "It would have cost us 50 times more because of the pressures, especially in North America, to get people out of the hospital very rapidly," said Yusuf. The heart-attack patients were given standard treatment when they arrived at the hospital, and then a third of them got a high dose of rivaparin, a second third got a lower-dose, and the remaining third got no additional treatment, Yusuf said. After seven days of treatment they saw a 13 percent reduction in death, heart attack and stroke in the patients who got rivaparin, which belongs to a class of drugs called heparins. After 30 days the benefits of treatment grew. Yusuf predicted that adding a heparin drug to the treatment people already get after heart attacks would save 500,000 to a million lives a year around the world. --More 0001 Local Time 2101 GMT
